[{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"American Regent","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"Guanylate cyclase (GC)","graph1":"Hematology","graph2":"Approved FDF","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Provepharm Life Solutions \/ Provepharm Life Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Provepharm Life Solutions \/ Provepharm Life Solutions"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Calyptus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Cetrorelix Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Provepharm Life Solutions \/ Provepharm Life Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Provepharm Life Solutions \/ Provepharm Life Solutions"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Indigo Carmine","moa":"None","graph1":"Urology","graph2":"Phase IV","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provepharm Life Solutions \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Provepharm Life Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Indigo Carmine","moa":"None","graph1":"Urology","graph2":"Phase IV","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provepharm Life Solutions \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Provepharm Life Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Indigo Carmine","moa":"None","graph1":"Urology","graph2":"Phase IV","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provepharm Life Solutions \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Provepharm Life Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"3,3\\'-Dioxo-2,2\\'-bisindolylidene-5,5\\'-disulfonate Disodium","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Provepharm Life Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Provepharm Life Solutions \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Provence Technologies SAS

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 07, 2024

                          Lead Product(s) : Indigo Carmine

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 16, 2023

                          Lead Product(s) : Indigo Carmine

                          Therapeutic Area : Urology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 26, 2023

                          Lead Product(s) : Indigo Carmine

                          Therapeutic Area : Urology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Provepharm acquired global rights of the Cetrorelix acetate from Calyptus and will take on all development activities and ultimately commercial distribution upon approval.

                          Product Name : Cetrorelix Acetate-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 22, 2022

                          Lead Product(s) : Cetrorelix Acetate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Recipient : Calyptus Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : ProvayBlue (methylene blue) is hypotonic and may be diluted before use in a solution of 50 mL 5% Dextrose Injection in order to avoid local pain, particularly in the pediatric population. Use the diluted solution immediately after preparation.

                          Product Name : ProvayBlue

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 30, 2022

                          Lead Product(s) : Methylene Blue

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved FDF

                          Recipient : American Regent

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Lead Product(s) : 3,3\'-Dioxo-2,2\'-bisindolylidene-5,5\'-disulfonate Disodium

                          Therapeutic Area : Urology

                          Study Phase : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 14, 2020

                          Lead Product(s) : 3,3\'-Dioxo-2,2\'-bisindolylidene-5,5\'-disulfonate Disodium

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 13, 2019

                          Lead Product(s) : Phenylephrine Hydrochloride

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Recipient : Carilion Clinic

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 10, 2018

                          Lead Product(s) : Methylene Blue

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank